icovamenib — Topline data
Q4 2026
Both trials include a 26-week primary endpoint, with topline data anticipated in the fourth quarter of 2026.Source filing
BMEA biotech catalysts & pipeline
BIOMEA FUSION INC · Data as of 2026-10-25
Upcoming catalysts
icovamenib — Topline data
Q1 2027
The trial is currently enrolling patients, with 26-week primary endpoint data expected in the first quarter of 2027.Source filing
icovamenib — Topline data
Q2 2027
The trial is currently enrolling patients, with 26-week primary endpoint data expected in the second quarter of 2027.Source filing